"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,EP,A4,EP 1670414 A4,104-942-130-421-55X,2007-09-26,2007,EP 04784465 A,2004-09-17,US 2004/0030607 W;;US 50910503 P,2003-10-06,USE OF CXCR4 PROTEIN EXPRESSION ON THE SURFACE OF STEM CELLS AS A MARKER FOR TUMOR TROPIC POTENTIAL,,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;EHTESHAM MONEEB,,https://lens.org/104-942-130-421-55X,Search Report,no,1,0,7,7,0,C12N5/0623;;C12N2501/11;;C12N2501/115;;G01N33/5017;;G01N33/5073;;G01N2333/715;;A61P35/00;;A61P37/04;;C12N5/0623;;G01N33/5017;;G01N33/5073;;G01N2333/715;;C12N2501/11;;C12N2501/115,C12N5/00;;A61K/;;C12N5/0797;;G01N33/50,,7,7,042-193-792-410-144;;132-376-219-466-529;;032-319-618-721-009;;024-815-965-010-503;;070-081-654-036-587;;094-001-368-355-534;;019-660-255-928-278,10.1097/00130404-200305000-00007;;12952304;;10.1016/s0378-4274(02)00432-0;;12628753;;12472902;;10.1046/j.1471-4159.2002.01260.x;;10.1002/glia.10139;;12655598;;12880376;;10.1517/14712598.3.5.759;;14550422;;10.1016/j.gde.2003.08.012;;10.1016/s0092-8674(00)80783-7;;10380923,"YIP STEPHEN ET AL: ""Neural stem cell biology may be well suited for improving brain tumor therapies."", CANCER JOURNAL (SUDBURY, MASS.) 2003 MAY-JUN, vol. 9, no. 3, May 2003 (2003-05-01), pages 189 - 204, XP009088246, ISSN: 1528-9117;;BONAVIA RUDY ET AL: ""Chemokines and their receptors in the CNS: Expression of CXCL12/SDF-1 and CXCR4 and their role in astrocyte proliferation."", TOXICOLOGY LETTERS (SHANNON), vol. 139, no. 2-3, 4 April 2003 (2003-04-04), pages 181 - 189, XP009088249, ISSN: 0378-4274;;LUO YONGQUAN ET AL: ""Microarray analysis of selected genes in neural stem and progenitor cells."", JOURNAL OF NEUROCHEMISTRY, vol. 83, no. 6, December 2002 (2002-12-01), pages 1481 - 1497, XP009088239, ISSN: 0022-3042;;LAZARINI FRANÇOISE ET AL: ""Role of the alpha-chemokine stromal cell-derived factor (SDF-1) in the developing and mature central nervous system."", GLIA 15 APR 2003, vol. 42, no. 2, 15 April 2003 (2003-04-15), pages 139 - 148, XP009088242, ISSN: 0894-1491;;KABOS PETER ET AL: ""Neural stem cells as delivery vehicles."", EXPERT OPINION ON BIOLOGICAL THERAPY AUG 2003, vol. 3, no. 5, August 2003 (2003-08-01), pages 759 - 770, XP009088259, ISSN: 1471-2598;;DOETSCH FIONA: ""A niche for adult neural stem cells."", CURRENT OPINION IN GENETICS & DEVELOPMENT, vol. 13, no. 5, October 2003 (2003-10-01), pages 543 - 550, XP009088241, ISSN: 0959-437X;;DOETSCH F ET AL: ""SUBVENTRICULAR ZONE ASTROCYTES ARE NEURAL STEM CELLS IN THE ADULT MAMMALIAN BRAIN"", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 97, 11 June 1999 (1999-06-11), pages 703 - 716, XP000942009, ISSN: 0092-8674",DISCONTINUED
2,US,A1,US 2008/0274086 A1,065-362-029-427-320,2008-11-06,2008,US 59846804 A,2004-09-17,US 59846804 A;;US 50910503 P;;US 2004/0030607 W,2003-10-06,Use of Cxcr4 Protein Expression on the Surface of Stem Cells as a Marker for Tumor Tropic Potential,"The present invention relates to tumor tropic stem cells, and particularly to neural stem cells, and their use as delivery vehicles for therapeutic gene products to neoplastic foci. The stem cells with tumor tropic potential are selected based on the stem cells exhibiting CXCR4 receptors or an affinity for the chemokine SDF-1. The stem cells may additionally exhibit markers characteristic of astrocytic progenitors. The stem cells may be administered as part of a treatment regimen including the chemokine SDF-1.",CEDARS SINAI MEDICAL CENTER,YU JOHN S;;EHTESHAM MONEEB,CEDARS-SINAI MEDICAL CENTER (2000-05-30),https://lens.org/065-362-029-427-320,Patent Application,yes,3,4,7,7,0,A61P35/00;;A61P37/04;;C12N5/0623;;C12N5/0623;;C12N2501/11;;C12N2501/11;;C12N2501/115;;C12N2501/115;;G01N33/5017;;G01N33/5017;;G01N33/5073;;G01N33/5073;;G01N2333/715;;G01N2333/715,A61K35/12;;A61K/;;A61P35/00;;C12N5/0797;;C12Q1/68;;G01N33/50,424/93.7;;435/368;;435/6,0,0,,,,DISCONTINUED
3,US,A1,US 2011/0256555 A1,024-640-139-713-977,2011-10-20,2011,US 201113163553 A,2011-06-17,US 201113163553 A;;US 59846804 A;;US 2004/0030607 W;;US 50910503 P,2003-10-06,USE OF CXCR4 PROTEIN EXPRESSION ON THE SURFACE OF STEM CELLS AS A MARKER FOR TUMOR TROPIC POTENTIAL,"The present invention relates to tumor tropic stem cells, and particularly to neural stem cells, and their use as delivery vehicles for therapeutic gene products to neoplastic foci. The stem cells with tumor tropic potential are selected based on the stem cells exhibiting CXCR4 receptors or an affinity for the chemokine SDF-1. The stem cells may additionally exhibit markers characteristic of astrocytic progenitors. The stem cells may be administered as part of a treatment regimen including the chemokine SDF-1.",CEDARS SINAI MEDICAL CENTER,YU JOHN S;;EHTESHAM MONEEB,CEDARS-SINAI MEDICAL CENTER (2000-05-03),https://lens.org/024-640-139-713-977,Patent Application,yes,0,3,7,7,0,A61P35/00;;A61P37/04;;C12N5/0623;;C12N5/0623;;C12N2501/11;;C12N2501/11;;C12N2501/115;;C12N2501/115;;G01N33/5017;;G01N33/5017;;G01N33/5073;;G01N33/5073;;G01N2333/715;;G01N2333/715,C12Q1/02;;A61K/;;C12N5/0797;;G01N33/50;;G01N33/53,435/7.21;;435/29,6,5,069-851-757-858-965;;029-482-332-556-361;;014-508-320-399-301;;076-166-592-795-617;;131-930-824-977-553,10.1038/31269;;9634238;;10.1006/dbio.1997.8592;;9205140;;10.1038/425247a;;13679899;;12384520;;10.1593/neo.3427;;15153341;;10.1593/neo.03427;;pmc1502097,"Zou et al., Nature, 393:595-599 1998.;;Hu et al., Chemokine receptor expression on human neural stem cells, Program No. 670.13. 2003 Neuroscience Meeting Planner: Preliminary Program. New Orleans, LA: Society for Neuroscience online September 2003.;;Kalyani et al., Developmental Biology, 186, 202-223, 1997.;;Bernards R. Cues for migration. Nature, 425:247-248, September 18, 2003.;;Ehtesham et al., Cancer Research 62:5657-5663, 2002;;Ehtesham et al., Neoplasia, 6(3):287-293, May/June 2004",DISCONTINUED
4,WO,A3,WO 2005/039488 A3,152-739-711-415-091,2006-11-30,2006,US 2004/0030607 W,2004-09-17,US 50910503 P,2003-10-06,USE OF CXCR4 PROTEIN EXPRESSION ON THE SURFACE OF STEM CELLS AS A MARKER FOR TUMOR TROPIC POTENTIAL,"The present invention relates to tumor tropic stem cells, and particularly to neural stem cells, and their use as delivery vehicles for therapeutic gene products to neoplastic foci. The stem cells with tumor tropic potential are selected based on the stem cells exhibiting CXCR4 receptors or an affinity for the chemokine SDF-1. The stem cells may additionally exhibit markers characteristic of astrocytic progenitors. The stem cells may be administered as part of a treatment regimen including the chemokine SDF-1.",CEDARS SINAI MEDICAL CENTER;;YU JOHN S;;EHTESHAM MONEEB,YU JOHN S;;EHTESHAM MONEEB,,https://lens.org/152-739-711-415-091,Search Report,yes,0,0,7,7,0,A61P35/00;;A61P37/04;;C12N5/0623;;C12N5/0623;;C12N2501/11;;C12N2501/11;;C12N2501/115;;C12N2501/115;;G01N33/5017;;G01N33/5017;;G01N33/5073;;G01N33/5073;;G01N2333/715;;G01N2333/715,G01N33/567;;A61K/;;C12N5/0797;;G01N33/50,,8,7,025-175-864-113-654;;011-346-871-848-320;;028-426-719-001-202;;047-367-409-926-543;;076-166-592-795-617;;061-569-982-320-061;;119-233-546-263-121,10.1038/sj.bmt.1703289;;11781610;;10.1111/j.1749-6632.2001.tb03571.x;;11458515;;11447341;;10.1097/00001756-200107200-00038;;9304697;;10.1016/s0301-0082(97)00020-8;;12384520;;10742153;;10.1038/74710;;12499252,"SPENCER A. ET AL.: ""Enumeration of bone marrow 'homing' haemopoietic stem cells from G-CSF-mobilised normal donora and influence on engraftment following allogeneic transplantation"", BONE MARROW TRANSPLANTATION, vol. 28, no. 11, 1 December 2001 (2001-12-01), pages 1019 - 1022, XP003002370;;MOHLE ET AL.: ""Transendothelial Migration of Hematopoietic Progenitor Cells"", ANN. NY ACAD. SCI., vol. 938, 2001, pages 26 - 34, XP008071049;;HUGNOT ET AL.: ""Regulation of glial differentiation of MHP36 neural multipotent cell line"", DEVELOPMENTAL NEUROSCIENCE, vol. 12, no. 10, July 2001 (2001-07-01), pages 2237 - 2241, XP008071051;;MURPHY M. ET AL.: ""Cytokines which signal through the lif receptor and their actions in the nervous system"", PROG. NEUROBIOL., vol. 52, no. 5, August 1997 (1997-08-01), pages 355 - 378, XP003002371;;EHTESHAM M. ET AL.: ""The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma"", CANCER RESEARCH, vol. 62, no. 20, 15 October 2002 (2002-10-15), pages 5657 - 5663, XP003002372;;BENEDETTI S. ET AL.: ""Gene therapy of experimental brain tumors using neural progenitor cells"", NATURE MEDICINE, vol. 6, no. 4, April 2000 (2000-04-01), pages 447 - 450, XP002943259;;EHTESHAM M. ET AL.: ""Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand"", CANCER RESEARCH, vol. 62, no. 24, 15 December 2002 (2002-12-15), pages 7170 - 7174, XP003002373;;See also references of EP 1670414A4",PENDING
5,EP,A2,EP 1670414 A2,146-771-851-827-509,2006-06-21,2006,EP 04784465 A,2004-09-17,US 2004/0030607 W;;US 50910503 P,2003-10-06,USE OF CXCR4 PROTEIN EXPRESSION ON THE SURFACE OF STEM CELLS AS A MARKER FOR TUMOR TROPIC POTENTIAL,,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;EHTESHAM MONEEB,,https://lens.org/146-771-851-827-509,Patent Application,yes,0,0,7,7,0,A61P35/00;;A61P37/04;;C12N5/0623;;C12N5/0623;;C12N2501/11;;C12N2501/11;;C12N2501/115;;C12N2501/115;;G01N33/5017;;G01N33/5017;;G01N33/5073;;G01N33/5073;;G01N2333/715;;G01N2333/715,C12N5/00;;A61K/;;C12N5/0797;;G01N33/50,,0,0,,,,DISCONTINUED
6,WO,A2,WO 2005/039488 A2,020-989-960-821-934,2005-05-06,2005,US 2004/0030607 W,2004-09-17,US 50910503 P,2003-10-06,USE OF CXCR4 PROTEIN EXPRESSION ON THE SURFACE OF STEM CELLS AS A MARKER FOR TUMOR TROPIC POTENTIAL,"The present invention relates to tumor tropic stem cells, and particularly to neural stem cells, and their use as delivery vehicles for therapeutic gene products to neoplastic foci. The stem cells with tumor tropic potential are selected based on the stem cells exhibiting CXCR4 receptors or an affinity for the chemokine SDF-1. The stem cells may additionally exhibit markers characteristic of astrocytic progenitors. The stem cells may be administered as part of a treatment regimen including the chemokine SDF-1.",CEDARS SINAI MEDICAL CENTER;;YU JOHN S;;EHTESHAM MONEEB,YU JOHN S;;EHTESHAM MONEEB,,https://lens.org/020-989-960-821-934,Patent Application,yes,0,2,7,7,0,A61P35/00;;A61P37/04;;C12N5/0623;;C12N5/0623;;C12N2501/11;;C12N2501/11;;C12N2501/115;;C12N2501/115;;G01N33/5017;;G01N33/5017;;G01N33/5073;;G01N33/5073;;G01N2333/715;;G01N2333/715,A61K/;;C12N5/0797;;G01N33/50,,1,0,,,See references of EP 1670414A4,PENDING
7,US,A1,US 2006/0148082 A1,067-295-580-004-00X,2006-07-06,2006,US 36439406 A,2006-02-28,US 36439406 A;;US 25375902 A;;US 33495701 P,2001-10-25,Method for delivering a biological compound using neural progenitor cells derived from whole bone marrow,"A method is described for generating a clinically significant volume of neural progenitor cells from whole bone marrow. A mass of bone marrow cells may be grown in a culture supplemented with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). Further methods of the present invention are directed to utilizing the neural progenitor cells cultured in this fashion in the treatment of various neuropathological conditions, and in targeting delivery of cells transfected with a particular gene to diseased or damaged tissue.",CEDARS SINAI MEDICAL CENTER,YU JOHN;;KABOS PETER;;EHTESHAM MONEEB,CEDARS-SINAI MEDICAL CENTER (2002-11-05),https://lens.org/067-295-580-004-00X,Patent Application,yes,44,0,19,19,0,A61K35/12;;A61K38/00;;A61K48/00;;C12N5/0623;;C12N2501/11;;C12N2501/115;;C12N2506/11;;C12N2510/00;;C12N2506/1353;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;C12N5/0623;;A61K35/12;;C12N2501/11;;C12N2506/11;;A61K38/00;;C12N2501/115;;C12N2510/00;;A61K48/00;;C12N2506/1353,A61K35/12;;A61K35/30;;A61K38/00;;A61K48/00;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;C12N5/0797,435/368,0,0,,,,EXPIRED
8,US,A1,US 2006/0029580 A1,138-583-912-624-580,2006-02-09,2006,US 23452005 A,2005-09-23,US 23452005 A;;US 25375902 A;;US 33495701 P,2001-10-25,Method for treating a condition with neural progenitor cells derived from whole bone marrow,"A method is described for generating a clinically significant volume of neural progenitor cells from whole bone marrow. A mass of bone marrow cells may be grown in a culture supplemented with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). Further methods of the present invention are directed to utilizing the neural progenitor cells cultured in this fashion in the treatment of various neuropathological conditions, and in targeting delivery of cells transfected with a particular gene to diseased or damaged tissue.",CEDARS SINAI MEDICAL CENTER,YU JOHN;;KABOS PETER;;EHTESHAM MONEEB,CEDARS-SINAI MEDICAL CENTER (2002-11-05),https://lens.org/138-583-912-624-580,Patent Application,yes,48,5,19,19,0,A61K35/12;;A61K38/00;;A61K48/00;;C12N5/0623;;C12N2501/11;;C12N2501/115;;C12N2506/11;;C12N2510/00;;C12N2506/1353;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;C12N5/0623;;A61K35/12;;C12N2501/11;;C12N2506/11;;A61K38/00;;C12N2501/115;;C12N2510/00;;A61K48/00;;C12N2506/1353,A61K35/12;;A61K45/00;;A61K35/30;;A61K38/00;;A61K38/18;;A61K48/00;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;C12N5/0797,424/93.7;;435/368,0,0,,,,DISCONTINUED
9,US,A1,US 2004/0057935 A1,080-450-287-927-532,2004-03-25,2004,US 25114802 A,2002-09-20,US 25114802 A,2002-09-20,Intratumoral delivery of dendritic cells,"
   Methods included herein describe the treatment of a tumor by administering dendritic cells either directly into the same or into its surrounding tissue. Further methods describe the induction of immune cell infiltration into tumors and the treatment of tumors with unprimed dendritic cells by administering dendritic cells in a similar fashion. The methods of the present invention are particularly advantageous in the treatment of brain tumors and other solid tumors disposed throughout the body of a mammal that are difficult or impossible to treat by conventional surgical means. Dendritic cell-based compositions effective in the treatment of such tumors are also described. 
",CEDARS SINAI MEDICAL CENTER,YU JOHN;;BLACK KEITH;;EHTESHAM MONEEB,CEDARS-SINAI MEDICAL CENTER (2002-11-05),https://lens.org/080-450-287-927-532,Patent Application,yes,8,29,1,1,0,A61K39/4644;;A61K39/4615;;A61K39/4611;;A61K39/4622;;A61K2039/5152;;A61K2039/5154;;A61K35/15,A61K39/00,424/93.7,0,0,,,,DISCONTINUED
10,US,A1,US 2006/0205074 A1,164-589-384-144-304,2006-09-14,2006,US 43399606 A,2006-05-15,US 43399606 A;;US 25375902 A;;US 33495701 P,2001-10-25,Neural progenitor cells derived from whole bone marrow,"A method is described for generating a clinically significant volume of neural progenitor cells from whole bone marrow. A mass of bone marrow cells may be grown in a culture supplemented with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). Further methods of the present invention are directed to utilizing the neural progenitor cells cultured in this fashion in the treatment of various neuropathological conditions, and in targeting delivery of cells transfected with a particular gene to diseased or damaged tissue.",CEDARS SINAI MEDICAL CENTER,YU JOHN;;KABOS PETER;;EHTESHAM MONEEB,CEDARS-SINAI MEDICAL CENTER (2002-11-05),https://lens.org/164-589-384-144-304,Patent Application,yes,53,0,19,19,0,A61K35/12;;A61K38/00;;A61K48/00;;C12N5/0623;;C12N2501/11;;C12N2501/115;;C12N2506/11;;C12N2510/00;;C12N2506/1353;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;C12N5/0623;;A61K35/12;;C12N2501/11;;C12N2506/11;;A61K38/00;;C12N2501/115;;C12N2510/00;;A61K48/00;;C12N2506/1353,A61K35/12;;A61K35/30;;A61K38/00;;A61K48/00;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;C12N5/0797,435/368,0,0,,,,EXPIRED
11,AT,T1,AT E513901 T1,148-015-789-919-013,2011-07-15,2011,AT 08075134 T,2002-10-18,US 33495701 P;;US 25375902 A,2001-10-25,NEURALE VORLÄUFERZELLEN,The present invention relates to a method for generating a clinically significant volume of neural progenitor cells. The method comprises providing a mass of cells obtained from a mammal including at least one stem cell; and culturing the mass of cells in a medium comprising fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF) to produce a clinically significant volume of neural progenitor cells. The invention also concerns neural progenitor cells per se and their use in the treatment of neuropathologic conditions.,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;KABOS PETER;;EHTESHAM MONEEB,,https://lens.org/148-015-789-919-013,Granted Patent,no,0,0,19,19,0,A61K35/12;;A61K38/00;;A61K48/00;;C12N5/0623;;C12N2501/11;;C12N2501/115;;C12N2506/11;;C12N2510/00;;C12N2506/1353;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;C12N5/0623;;A61K35/12;;C12N2501/11;;C12N2506/11;;A61K38/00;;C12N2501/115;;C12N2510/00;;A61K48/00;;C12N2506/1353,A61K35/12;;A61K35/30;;A61K38/00;;A61K48/00;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;C12N5/0797,,0,0,,,,EXPIRED
12,US,B2,US 7504100 B2,092-878-152-325-393,2009-03-17,2009,US 36439406 A,2006-02-28,US 36439406 A;;US 25375902 A;;US 33495701 P,2001-10-25,Method for delivering a biological compound using neural progenitor cells derived from whole bone marrow,"A method is described for generating a clinically significant volume of neural progenitor cells from whole bone marrow. A mass of bone marrow cells may be grown in a culture supplemented with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). Further methods of the present invention are directed to utilizing the neural progenitor cells cultured in this fashion in the treatment of various neuropathological conditions, and in targeting delivery of cells transfected with a particular gene to diseased or damaged tissue.",CEDARS SINAI MEDICAL CENTER,YU JOHN S;;KABOS PETER;;EHTESHAM MONEEB,CEDARS-SINAI MEDICAL CENTER (2002-11-05),https://lens.org/092-878-152-325-393,Granted Patent,yes,48,8,19,19,0,A61K35/12;;A61K38/00;;A61K48/00;;C12N5/0623;;C12N2501/11;;C12N2501/115;;C12N2506/11;;C12N2510/00;;C12N2506/1353;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;C12N5/0623;;A61K35/12;;C12N2501/11;;C12N2506/11;;A61K38/00;;C12N2501/115;;C12N2510/00;;A61K48/00;;C12N2506/1353,A61K48/00;;A61K35/12;;A61K35/30;;A61K38/00;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;C12N5/0797,424/93.21;;424/93.1;;424/93.2;;435/325,23,22,002-139-557-983-569;;010-384-751-117-76X;;037-475-853-172-384;;072-202-121-867-696;;102-881-587-743-592;;082-231-208-545-177;;002-484-834-539-43X;;012-177-818-988-764;;159-966-370-938-701;;003-096-082-862-593;;042-899-467-629-059;;013-999-068-412-238;;015-375-563-301-698;;041-128-004-154-032;;015-459-933-949-167;;026-395-951-813-684;;121-160-166-447-41X;;052-591-144-757-648;;013-647-036-572-027;;092-482-123-514-901;;155-117-251-325-02X;;013-326-693-674-448,10722392;;10.1126/science.287.5457.1421;;9034785;;10.1210/edrv.18.1.0292;;10.1210/er.18.1.26;;11099418;;10.1126/science.290.5497.1775;;10.1073/pnas.94.8.4080;;pmc20571;;9108108;;10.1146/annurev.neuro.18.1.159;;10.1146/annurev.ne.18.030195.001111;;7605059;;10688783;;10.1126/science.287.5457.1433;;10585297;;10.1006/excr.1999.4678;;pmc6573198;;10.1523/jneurosci.17-15-05820.1997;;9221780;;1689217;;10.1016/0092-8674(90)90662-x;;12383233;;10.1046/j.1460-9568.2002.02181.x;;10.1126/science.290.5497.1779;;11099419;;10.1634/stemcells.18-4-295;;10924096;;9585351;;10.1002/ana.410430505;;10915564;;10.1006/exnr.2000.7389;;9874150;;10.1016/s0165-0270(98)00126-5;;11533656;;10.1038/ncb0901-778;;10.1126/science.287.5457.1418;;10722390;;10636772;;10.1126/science.286.5448.2238;;10.1126/science.287.5457.1442;;10688785;;10931522;;10.1002/1097-4547(20000815)61:4<364::aid-jnr2>3.0.co;2-c;;10.1002/1097-4547(20000815)61:4<364::aid-jnr2>3.3.co;2-3;;10.1038/nm1064;;15272269;;10.1006/exnr.1998.6998;;10192778,"Barinaga, M., Fetal Neuron Grafts Pave The Way For Stem Cell Therapies, The American Association For The Advancement Of Science, (Feb. 25, 2000), pp. 1421-1422, 287(5457).;;Bikfalvi et al., Biological Roles Of Fibroblast Growth Factor-2, Endocrine Reviews, ( Feb. 1997), pp. 26-45, 18(1).;;Brazelton et al., From Marrow to Brain: Expression Of Neuronal Phenotypes In Adult Mice, Science, (Dec. 1, 2000), pp. 1775-1779, 290.;;Eglitis et al., Hematopoietic Cells Differentiate Into Both Microglia And Macroglia In The Brains Of Adult Mice, Proceedings of the National Academy of Science USA/Neurobiology, (Apr. 1997), pp. 4080-4085, 94.;;Englund et al., Site-Specific Neuronal Differentiation Of Growth Factor Expanded Human Neural Progenitor Cells After Transplantation To The Neonatal Rat Brain, Society For Neuroscience Abstracts, (1999), p. 213, 23(1/2).;;Gage et al., Isolation, Characterization, And Use Of Stem Cells From The CNS, Annual Review Of Neuroscience, (1995), pp. 159-192, 18.;;Gage, F.H., Mammalian Neural Stem Cells, Science, (Feb. 25, 2000), pp. 1433-1438, 287.;;Johansson et al., Neural Stem Cells In The Adult Human Brain, Experimental Cell Research, (1999), pp. 733-736, 253.;;Kuhn et al., Epidermal Growth Factor And Fibroblast Growth Factor-2 Have Different Effects On Neural Progenitors In The Adult Rat Brain, Journal Of Neuroscience, (1997), pp. 5820-5829, 17(15).;;Lendahl et al., CNS Stem Cells Express A New Class Of Intermediate Filament Protein, Cell, (Feb. 23, 1990), pp. 585-595, 60(4).;;Martens et al., In Vivo Infusions Of Exogenous Growth Factors Into The Fourth Ventricle Of The AdultMouse Brain Increase The Proliferation Of Neural Progenitors Around The Fourth Ventricle And The Central Canal Of The Spinal Cord, European Journal Neuroscience, (2002), p. 1045-1057, 16(6).;;Mezey et al., Turning Blood In Brain: Cells Bearing Neuronal Antigens Generated In Vivo From Bone Marrow, Science, (Dec. 1, 2000), pp. 1779-1782, 290.;;Pagano et al., Isolation And Characterization Of Neural Stem Cells From The Adult Human Olfactory Bulb, Stem Cells, (2000), pp. 295-300, 18.;;Pincus et al., Fibroblast Growth Factor-2/Brain Derived Neurotrophic Factor-Associated Maturation Of New Neurons Generated From Adult Human Subependymal Cells, Annals of Neurology, (May 1998), pp. 576-585, 43(5).;;Sanchez-Ramos et al., Adult Bone Marrow Stromal Cells Differentiate Into Neural Cells In Vitro, Experimental Neurology, (2000), pp. 247-256, 164.;;Svendsen et al., A New Method For Rapid And Long Term Growth Of Human Neural Precursor Cells, Journal Of Neuroscience Methods, (Dec. 1, 1998), pp. 141-152, 85(2).;;Toma et al., Isolation Of Multipotent Adult Stem Cells From The Dermis Of Mammalian Skin, Nature Cell Biology, (Sep. 2001), pp. 778-784, 3.;;Vogel, G., Can Old Cells Learn New Tricks, The American Association For The Advancement Of Science, (Feb. 25, 2000). pp. 1418-1419, 287(5457).;;Vogel, G., Capturing The Promise Of Youth, The American Association For The Advancement Of Science, (Dec. 17, 1999), pp. 2238-2239, 286(5448).;;Weissman, I.L., Translating Stem And Progenitor Cell Biology To The Clinic: Barriers And Opportunities, The American Association For The Advancement Of Science, (Feb. 25, 2000), pp. 1442-1446, 287(5457).;;Woodbury et al., Adult Rat And Human Bone Marrow Stronal Cells Differentiate Into Neurons, Journal Of Neuroscience Research, (2000), pp. 364-370, 61.;;Lindavall et al., Stem Cell Therapy For Human Neurodegenerative Disorders-How To Make It Work, Nature Medicine, (Jul. 2004), pp. S52-S50, 10.;;Vescovi et al., Isolation and Cloning of Multipotential Stem Cells From The Embryonic Human CNS and Establishment of Transplantable Human Neural Stem Cell Lines By Epigenetic Simulation, Experimental Neurology, (1999), pp. 71-83, 156.",EXPIRED
13,US,B2,US 8071366 B2,135-466-696-081-451,2011-12-06,2011,US 43399606 A,2006-05-15,US 43399606 A;;US 25375902 A;;US 33495701 P,2001-10-25,Neural progenitor cells derived from whole bone marrow,"A method is described for generating a clinically significant volume of neural progenitor cells from whole bone marrow. A mass of bone marrow cells may be grown in a culture supplemented with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). Further methods of the present invention are directed to utilizing the neural progenitor cells cultured in this fashion in the treatment of various neuropathological conditions, and in targeting delivery of cells transfected with a particular gene to diseased or damaged tissue.",YU JOHN S;;KABOS PETER;;EHTESHAM MONEEB;;CEDARS SINAI MEDICAL CENTER,YU JOHN S;;KABOS PETER;;EHTESHAM MONEEB,CEDARS-SINAI MEDICAL CENTER (2002-11-05),https://lens.org/135-466-696-081-451,Granted Patent,yes,66,0,19,19,0,A61K35/12;;A61K38/00;;A61K48/00;;C12N5/0623;;C12N2501/11;;C12N2501/115;;C12N2506/11;;C12N2510/00;;C12N2506/1353;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;C12N5/0623;;A61K35/12;;C12N2501/11;;C12N2506/11;;A61K38/00;;C12N2501/115;;C12N2510/00;;A61K48/00;;C12N2506/1353,C12N5/0797;;A61K35/12;;A61K35/30;;A61K38/00;;A61K48/00;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;C12N5/074,435/325;;435/372;;435/377;;435/368,43,25,033-195-476-251-906;;002-139-557-983-569;;010-384-751-117-76X;;037-475-853-172-384;;072-202-121-867-696;;102-881-587-743-592;;082-231-208-545-177;;002-484-834-539-43X;;012-177-818-988-764;;159-966-370-938-701;;003-096-082-862-593;;042-899-467-629-059;;013-999-068-412-238;;015-375-563-301-698;;041-128-004-154-032;;015-459-933-949-167;;026-395-951-813-684;;121-160-166-447-41X;;052-591-144-757-648;;013-647-036-572-027;;092-482-123-514-901;;155-117-251-325-02X;;013-326-693-674-448;;083-624-957-368-589;;135-015-423-848-394,pmc19936;;9520466;;10.1073/pnas.95.7.3908;;10722392;;10.1126/science.287.5457.1421;;9034785;;10.1210/edrv.18.1.0292;;10.1210/er.18.1.26;;11099418;;10.1126/science.290.5497.1775;;10.1073/pnas.94.8.4080;;pmc20571;;9108108;;10.1146/annurev.neuro.18.1.159;;10.1146/annurev.ne.18.030195.001111;;7605059;;10688783;;10.1126/science.287.5457.1433;;10585297;;10.1006/excr.1999.4678;;pmc6573198;;10.1523/jneurosci.17-15-05820.1997;;9221780;;1689217;;10.1016/0092-8674(90)90662-x;;12383233;;10.1046/j.1460-9568.2002.02181.x;;10.1126/science.290.5497.1779;;11099419;;10.1634/stemcells.18-4-295;;10924096;;9585351;;10.1002/ana.410430505;;10915564;;10.1006/exnr.2000.7389;;9874150;;10.1016/s0165-0270(98)00126-5;;11533656;;10.1038/ncb0901-778;;10.1126/science.287.5457.1418;;10722390;;10636772;;10.1126/science.286.5448.2238;;10.1126/science.287.5457.1442;;10688785;;10931522;;10.1002/1097-4547(20000815)61:4<364::aid-jnr2>3.0.co;2-c;;10.1002/1097-4547(20000815)61:4<364::aid-jnr2>3.3.co;2-3;;10.1038/nm1064;;15272269;;10.1006/exnr.1998.6998;;10192778;;10.1042/cs20040276;;15462670;;10.1126/science.1086071;;14526083,"Azizi et al., Proc. Natl. Acad. Sci. USA vol. 95, pp. 3908-3913, Mar. 1998.;;Barinaga, M., Fetal Neuron Grafts Pave the Way for Stem Cell Therapies, The American Association for the Advancement of Science, (Feb. 25, 2000), pp. 1421-1422, 287(5457).;;Bikfalvi et al., Biological Roles of Fibroblast Growth Factor-2, Endocrine Reviews, ( Feb. 1997), pp. 26-45, 18(1).;;Brazelton et al., From Marrow to Brain: Expression of Neuronal Phenotypes in Adult Mice, Science, (Dec. 1, 2000), pp. 1775-1779, 290.;;Eglitis et al., Hematopoietic Cells Differentiate Into Both Microglia and Macroglia in the Brains of Adult Mice, Proceedings of the National Academy of Science USA/Neurobiology, (Apr. 1997), pp. 4080-4085, 94.;;Englund et al., Site-Specific Neuronal Differentiation of Growth Factor Expanded Human Neural Progenitor Cells After Transplantation to the Neonatal Rat Brain, Society for Neuroscience Abstracts, (1999), p. 213, 23(1/2).;;Gage et al., Isolation, Characterization, and Use of Stem Cells From the CNS, Annual Review of Neuroscience, (1995), pp. 159-192, 18.;;Gage, F.H., Mammalian Neural Stem Cells, Science, (Feb. 25, 2000), pp. 1433-1438, 287.;;Johansson et al., Neural Stem Cells in the Adult Human Brain, Experimental Cell Research, (1999), pp. 733-736, 253.;;Kuhn et al., Epidermal Growth Factor and Fibroblast Growth Factor-2 Have Different Effects on Neural Progenitors in the Adult Rat Brain, Journal of Neuroscience, (1997), pp. 5820-5829, 17(15).;;Lendahl et al., CNS Stem Cells Express a New Class of Intermediate Filament Protein, Cell, (Feb. 23, 1990), pp. 585-595, 60(4).;;Martens et al., In Vivo Infusions of Exogenous Growth Factors Into the Fourth Ventricle of the AdultMouse Brain Increase the Proliferation of Neural Progenitors Around the Fourth Ventricle and the Central Canal of the Spinal Cord, European Journal Neuroscience, (2002), p. 1045-1057, 16(6).;;Mezey et al., Turning Blood in Brain: Cells Bearing Neuronal Antigens Generated in Vivo From Bone Marrow, Science, (Dec. 1, 2000), pp. 1779-1782, 290.;;Pagano et al., Isolation and Characterization of Neural Stem Cells From the Adult Human Olfactory Bulb, Stem Cells, (2000), pp. 295-300, 18.;;Pincus et al., Fibroblast Growth Factor-2/Brain Derived Neurotrophic Factor-Associated Maturation of New Neurons Generated From Adult Human Subependymal Cells, Annals of Neurology, (May 1998), pp. 576-585, 43(5).;;Sanchez-Ramos et al., Adult Bone Marrow Stromal Cells Differentiate Into Neural Cells in Vitro, Experimental Neurology, (2000), pp. 247-256, 164.;;Svendsen et al., A New Method for Rapid and Long Term Growth of Human Neural Precursor Cells, Journal of Neuroscience Methods, (Dec. 1, 1998), pp. 141-152, 85(2).;;Toma et al., Isolation of Multipotent Adult Stem Cells From the Dermis of Mammalian Skin, Nature Cell Biology, (Sep. 2001), pp. 778-784, 3.;;Vogel, G., Can Old Cells Learn New Tricks, The American Association for the Advancement of Science, (Feb. 25, 2000), pp. 1418-1419, 287(5457).;;Vogel, G., Capturing the Promise of Youth, The American Association for the Advancement of Science, (Dec. 17, 1999), pp. 2238-2239, 286(5448).;;Weissman, I.L., Translating Stem and Progenitor Cell Biology to the Clinic: Barriers and Opportunities, The American Association for the Advancement of Science, (Feb. 25, 2000), pp. 1442-1446, 287(5457).;;Woodbury et al., Adult Rat and Human Bone Marrow Stronal Cells Differentiate Into Neurons, Journal of Neuroscience Research, (2000), pp. 364-370, 61.;;Lindvall et al., Stem Cell Therapy for Human Neurodegenerative Disorders-How to Make It Work, Nature Medicine, (Jul. 2004), pp. S42-S50, 10.;;Vescovi et al., Isolation and Cloning of Multipotential Stem Cells From the Embryonic Human CNS and Establishment of Transplantable Human Neural Stem Cell Lines by Epigenetic Stimulation, Experimental Neurology, (1999), pp. 71-83, 156.;;Bithell et al, Neural Stem Cells and Cell Replacement Therapy: Making the Right Cells, Clinical Science, (2005), pp. 13-22, 108.;;Clement et al., Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons, Science, (Oct. 3, 2003), pp. 113-117, 302.;;PCT/US2002/33447 ISR dated Mar. 10, 2003.;;EP02784173 Exam Report dated Jun. 6, 2005.;;EP02784173 Exam Report dated Mar. 9, 2007.;;EP08075134 Extended Search Report dated Jul. 14, 2008.;;EP08075134 Exam Report dated Oct. 15, 2008.;;EP08075134 Exam Report dated Oct. 29, 2009.;;JP2003-538356 Exam Report dated Jul. 4, 2007.;;JP2003-538356 Exam Report dated Apr. 23, 2009.;;U.S. Appl. No. 10/253,759 Office Action dated Jan. 13, 2005.;;U.S. Appl. No. 10/253,759 Office Action dated May 4, 2005.;;U.S. Appl. No. 10/253,759 Notice of Allowance dated Dec. 14, 2005.;;U.S. Appl. No. 11/234,520 Office Action dated Dec. 27, 2007.;;U.S. Appl. No. 11/234,520 Office Action dated Oct. 20, 2008.;;U.S. Appl. No. 11/364,454 Office Action dated Jan. 28, 2008.;;U.S. Appl. No. 11/364,454 Office Action dated Apr. 3, 2008.;;U.S. Appl. No. 11/364,394 Office Action dated Mar. 21, 2008.;;U.S. Appl. No. 11/364,394 Notice of Allowance dated Nov. 17, 2008.",INACTIVE
14,EP,A1,EP 1438393 A1,151-301-119-033-622,2004-07-21,2004,EP 02784173 A,2002-10-18,US 0233447 W;;US 33495701 P;;US 25375902 A,2001-10-25,DIFFERENTIATION OF WHOLE BONE MARROW,The present invention relates to a method for generating a clinically significant volume of neural progenitor cells. The method comprises providing a mass of cells obtained from a mammal including at least one stem cell; and culturing the mass of cells in a medium comprising fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF) to produce a clinically significant volume of neural progenitor cells. The invention also concerns neural progenitor cells per se and their use in the treatment of neuropathologic conditions.,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;KABOS PETER;;EHTESHAM MONEEB,"CEDARS-SINAI MEDICAL CENTER, US (2013-12-13)",https://lens.org/151-301-119-033-622,Patent Application,yes,0,1,19,19,0,A61K35/12;;A61K38/00;;A61K48/00;;C12N5/0623;;C12N2501/11;;C12N2501/115;;C12N2506/11;;C12N2510/00;;C12N2506/1353;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;C12N5/0623;;A61K35/12;;C12N2501/11;;C12N2506/11;;A61K38/00;;C12N2501/115;;C12N2510/00;;A61K48/00;;C12N2506/1353,A61K35/12;;A61K35/30;;A61K38/00;;A61K48/00;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;C12N5/0797,,0,0,,,,EXPIRED
15,EP,B1,EP 1438393 B1,010-763-390-876-065,2008-02-27,2008,EP 02784173 A,2002-10-18,US 0233447 W;;US 33495701 P;;US 25375902 A,2001-10-25,DIFFERENTIATION OF WHOLE BONE MARROW,The present invention relates to a method for generating a clinically significant volume of neural progenitor cells. The method comprises providing a mass of cells obtained from a mammal including at least one stem cell; and culturing the mass of cells in a medium comprising fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF) to produce a clinically significant volume of neural progenitor cells. The invention also concerns neural progenitor cells per se and their use in the treatment of neuropathologic conditions.,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;KABOS PETER;;EHTESHAM MONEEB,"CEDARS-SINAI MEDICAL CENTER, US (2013-12-13)",https://lens.org/010-763-390-876-065,Granted Patent,yes,2,0,19,19,0,A61K35/12;;A61K38/00;;A61K48/00;;C12N5/0623;;C12N2501/11;;C12N2501/115;;C12N2506/11;;C12N2510/00;;C12N2506/1353;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;C12N5/0623;;A61K35/12;;C12N2501/11;;C12N2506/11;;A61K38/00;;C12N2501/115;;C12N2510/00;;A61K48/00;;C12N2506/1353,A61K35/12;;A61K35/30;;A61K38/00;;A61K48/00;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;C12N5/0797,,4,0,,,"ENGLUND U ET AL: ""SITE-SPECIFIC NEURONAL DIFFERENTIATION OF GROWTH FACTOR EXPANDED HUMAN NEURAL PROGENITOR CELLS AFTER TRANSPLANTATION TO THE NEONATALRAT BRAIN"" SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, vol. 25, no. 1/2, 1999, page 213 XP001002083 ISSN: 0190-5295;;KUHN H GEORG ET AL: ""Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain."" JOURNAL OF NEUROSCIENCE, vol. 17, no. 15, 1997, pages 5820-5829, XP002229396 ISSN: 0270-6474;;GAGE F H: ""MAMMALIAN NEURAL STEM CELLS"" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 287, no. 5457, 25 February 2000 (2000-02-25), pages 1433-1438, XP000919227 ISSN: 0036-8075;;MARTENS DAVID J ET AL: ""In vivo infusions of exogenous growth factors into the fourth ventricle of the adult mouse brain increase the proliferation of neural progenitors around the fourth ventricle and the central canal of the spinal cord."" EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 16, no. 6, September 2002 (2002-09), pages 1045-1057, XP002229397 September, 2002 ISSN: 0953-816X",EXPIRED
16,JP,A,JP 2008099709 A,021-725-872-067-377,2008-05-01,2008,JP 2007338253 A,2007-12-27,US 33495701 P;;US 25375902 A,2001-10-25,DIFFERENTIATION OF WHOLE BONE MARROW,"<P>PROBLEM TO BE SOLVED: To provide a method for efficiently generating neural progenitor cells for using in the treatment of neuropathy in a large scale. <P>SOLUTION: The method for generating a clinically significant volume of neural progenitor cells is provided. The method comprises a process for providing a mass of cells containing at least one stem cell and obtained from a mammal, and a process for producing the clinically significant volume of neural progenitor cells by culturing at least one stem cell in a medium containing fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). The mass of bone marrow cells can be grown in a culture supplemented with the fibroblast growth factor-2 (FGF-2) and the epidermal growth factor (EGF). The method is further applied to bring the neural progenitor cells cultured by this way to be targeted in treating various neuropathological conditions so that the cells transfected with a particular gene are delivered to diseased or damaged tissues. <P>COPYRIGHT: (C)2008,JPO&INPIT",CEDARS SINAI MEDICAL CENTER,YU JOHN S;;KABOS PETER;;EHTESHAM MONEEB,,https://lens.org/021-725-872-067-377,Patent Application,no,0,1,19,19,0,A61K35/12;;A61K38/00;;A61K48/00;;C12N5/0623;;C12N2501/11;;C12N2501/115;;C12N2506/11;;C12N2510/00;;C12N2506/1353;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;C12N5/0623;;A61K35/12;;C12N2501/11;;C12N2506/11;;A61K38/00;;C12N2501/115;;C12N2510/00;;A61K48/00;;C12N2506/1353,A61K35/12;;A61K35/28;;A61K35/30;;A61K38/00;;A61K48/00;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;C12N5/0797,,0,0,,,,DISCONTINUED
17,DE,T2,DE 60225310 T2,069-147-602-609-738,2009-03-12,2009,DE 60225310 T,2002-10-18,US 33495701 P;;US 25375902 A;;US 0233447 W,2001-10-25,DIFFERENZIERUNG VOM GESAMTEN KNOCHENMARK,The present invention relates to a method for generating a clinically significant volume of neural progenitor cells. The method comprises providing a mass of cells obtained from a mammal including at least one stem cell; and culturing the mass of cells in a medium comprising fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF) to produce a clinically significant volume of neural progenitor cells. The invention also concerns neural progenitor cells per se and their use in the treatment of neuropathologic conditions.,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;KABOS PETER;;EHTESHAM MONEEB,,https://lens.org/069-147-602-609-738,Granted Patent,no,0,0,19,19,0,A61K35/12;;A61K38/00;;A61K48/00;;C12N5/0623;;C12N2501/11;;C12N2501/115;;C12N2506/11;;C12N2510/00;;C12N2506/1353;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;C12N5/0623;;A61K35/12;;C12N2501/11;;C12N2506/11;;A61K38/00;;C12N2501/115;;C12N2510/00;;A61K48/00;;C12N2506/1353,A61K35/12;;A61K35/30;;A61K38/00;;A61K48/00;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;C12N5/0797,,0,0,,,,EXPIRED
18,DE,D1,DE 60225310 D1,080-489-655-899-060,2008-04-10,2008,DE 60225310 T,2002-10-18,US 33495701 P;;US 25375902 A;;US 0233447 W,2001-10-25,DIFFERENZIERUNG VOM GESAMTEN KNOCHENMARK,The present invention relates to a method for generating a clinically significant volume of neural progenitor cells. The method comprises providing a mass of cells obtained from a mammal including at least one stem cell; and culturing the mass of cells in a medium comprising fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF) to produce a clinically significant volume of neural progenitor cells. The invention also concerns neural progenitor cells per se and their use in the treatment of neuropathologic conditions.,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;KABOS PETER;;EHTESHAM MONEEB,,https://lens.org/080-489-655-899-060,Granted Patent,no,0,0,19,19,0,A61K35/12;;A61K38/00;;A61K48/00;;C12N5/0623;;C12N2501/11;;C12N2501/115;;C12N2506/11;;C12N2510/00;;C12N2506/1353;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;C12N5/0623;;A61K35/12;;C12N2501/11;;C12N2506/11;;A61K38/00;;C12N2501/115;;C12N2510/00;;A61K48/00;;C12N2506/1353,A61K35/12;;A61K35/30;;A61K38/00;;A61K48/00;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;C12N5/0797,,0,0,,,,EXPIRED
19,EP,B1,EP 1956079 B1,022-904-477-291-870,2011-06-22,2011,EP 08075134 A,2002-10-18,EP 02784173 A;;US 33495701 P;;US 25375902 A,2001-10-25,Neural progenitor cells,The present invention relates to a method for generating a clinically significant volume of neural progenitor cells. The method comprises providing a mass of cells obtained from a mammal including at least one stem cell; and culturing the mass of cells in a medium comprising fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF) to produce a clinically significant volume of neural progenitor cells. The invention also concerns neural progenitor cells per se and their use in the treatment of neuropathologic conditions.,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;KABOS PETER;;EHTESHAM MONEEB,,https://lens.org/022-904-477-291-870,Granted Patent,yes,2,0,19,19,0,A61K35/12;;A61K38/00;;A61K48/00;;C12N5/0623;;C12N2501/11;;C12N2501/115;;C12N2506/11;;C12N2510/00;;C12N2506/1353;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;C12N5/0623;;A61K35/12;;C12N2501/11;;C12N2506/11;;A61K38/00;;C12N2501/115;;C12N2510/00;;A61K48/00;;C12N2506/1353,C12N5/071;;A61K35/12;;A61K35/30;;A61K38/00;;A61K48/00;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;C12N5/0797,,2,0,,,"ENGLUND U ET AL: ""SITE-SPECIFIC NEURONAL DIFFERENTIATION OF GROWTH FACTOR EXPANDED HUMAN NEURAL PROGENITOR CELLS AFTER TRANSPLANTATION TO THE NEONATALRAT BRAIN"" SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, vol. 25, no. 1/2, 1999, page 213, XP001002083 ISSN: 0190-5295;;SANCHEZ-RAMOS J ET AL: ""Adult bone marrow stromal cells differentiate into neural cells in vitro"" 1 August 2000 (2000-08-01), EXPERIMENTAL NEUROLOGY, ACADEMIC PRESS, NEW YORK, NY, US, PAGE(S) 247 - 256 , XP002199139 ISSN: 0014-4886 * the whole document *",EXPIRED
20,US,A1,US 2006/0148083 A1,063-329-339-821-553,2006-07-06,2006,US 36445406 A,2006-02-28,US 36445406 A;;US 25375902 A;;US 33495701 P,2001-10-25,Differentiation of brain tissue,"A method is described for generating a clinically significant volume of neural progenitor cells from whole bone marrow. A mass of bone marrow cells may be grown in a culture supplemented with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). Further methods of the present invention are directed to utilizing the neural progenitor cells cultured in this fashion in the treatment of various neuropathological conditions, and in targeting delivery of cells transfected with a particular gene to diseased or damaged tissue.",CEDARS SINAI MEDICAL CENTER,YU JOHN S;;KABOS PETER;;EHTESHAM MONEEB,CEDARS-SINAI MEDICAL CENTER (2002-11-05),https://lens.org/063-329-339-821-553,Patent Application,yes,8,5,19,19,0,A61K35/12;;A61K38/00;;A61K48/00;;C12N5/0623;;C12N2501/11;;C12N2501/115;;C12N2506/11;;C12N2510/00;;C12N2506/1353;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;C12N5/0623;;A61K35/12;;C12N2501/11;;C12N2506/11;;A61K38/00;;C12N2501/115;;C12N2510/00;;A61K48/00;;C12N2506/1353,A61K35/12;;A61K35/30;;A61K38/00;;A61K48/00;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;C12N5/0797,435/368,0,0,,,,DISCONTINUED
21,EP,A1,EP 1705992 A1,095-193-499-082-498,2006-10-04,2006,EP 04703716 A,2004-01-20,US 2004/0001612 W,2004-01-20,INTRATUMORAL DELIVERY OF DENDRITIC CELLS,,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;BLACK KEITH;;EHTESHAM MONEEB,,https://lens.org/095-193-499-082-498,Patent Application,yes,0,0,2,2,0,A61K2039/54;;A61K39/4644;;A61K39/4622;;A61K39/4615;;A61K2239/46;;A61K39/4614;;A61K2239/31,A01N63/00;;A61K35/14;;A61K35/16;;A61K39/00;;C12N5/08,,0,0,,,,DISCONTINUED
22,WO,A1,WO 2005/079581 A1,006-865-743-750-12X,2005-09-01,2005,US 2004/0001612 W,2004-01-20,US 2004/0001612 W,2004-01-20,INTRATUMORAL DELIVERY OF DENDRITIC CELLS,Methods included herein describe the treatment of a tumor by administering dendritic cells either directly into the same or into its surrounding tissue. Further methods describe the induction of immune cell infiltration into tumors and the treatment of tumors with unprimed dendritic cells by administering dendritic cells in a similar fashion. The methods of the present invention are particularly advantageous in the treatment of brain tumors and other solid tumors disposed throughout the body of a mammal that are difficult or impossible to treat by conventional surgical means. Dendritic cell-based compositions effective in the treatment of such tumors are also described.,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;BLACK KEITH;;EHTESHAM MONEEB,,https://lens.org/006-865-743-750-12X,Patent Application,yes,0,12,2,2,0,A61K2039/54;;A61K39/4644;;A61K39/4622;;A61K39/4615;;A61K2239/46;;A61K39/4614;;A61K2239/31,A01N63/00;;A61K35/14;;A61K35/16;;A61K39/00;;C12N5/08,,2,2,080-647-403-540-300;;044-750-837-062-887,11221866;;12616102;;10.1097/00002371-200303000-00003,"YU J S ET AL: ""Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration"", vol. 61, 1 February 2001 (2001-02-01), pages 842 - 847, XP002983453;;EHTESHAM M ET AL: ""Intratumoral dendritic cell vaccination elitics potent tumroicidal immunity against malignant glioma in rats"", JOURNAL OF IMMUNOTHERAPY, vol. 26, no. 2, March 2003 (2003-03-01), pages 107 - 116, XP002983473",PENDING
23,US,B2,US 7129034 B2,027-342-910-951-180,2006-10-31,2006,US 25375902 A,2002-09-24,US 25375902 A;;US 33495701 P,2001-10-25,Differentiation of whole bone marrow,"A method is described for generating a clinically significant volume of neural progenitor cells from whole bone marrow. A mass of bone marrow cells may be grown in a culture supplemented with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). Further methods of the present invention are directed to utilizing the neural progenitor cells cultured in this fashion in the treatment of various neuropathological conditions, and in targeting delivery of cells transfected with a particular gene to diseased or damaged tissue.",CEDARS SINAI MEDICAL CENTER,YU JOHN S;;KABOS PETER;;EHTESHAM MONEEB,CEDARS-SINAI MEDICAL CENTER (2002-11-05),https://lens.org/027-342-910-951-180,Granted Patent,yes,43,11,19,19,0,A61K35/12;;A61K38/00;;A61K48/00;;C12N5/0623;;C12N2501/11;;C12N2501/115;;C12N2506/11;;C12N2510/00;;C12N2506/1353;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;C12N5/0623;;A61K35/12;;C12N2501/11;;C12N2506/11;;A61K38/00;;C12N2501/115;;C12N2510/00;;A61K48/00;;C12N2506/1353,C12N5/00;;A61K35/12;;A61K35/30;;A61K38/00;;A61K48/00;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;C12N5/0797;;C12N5/10,435/1.1;;435/377;;435/372;;435/325;;435/368,26,25,102-881-587-743-592;;010-384-751-117-76X;;015-459-933-949-167;;001-915-574-208-17X;;012-177-818-988-764;;082-231-208-545-177;;003-096-082-862-593;;015-375-563-301-698;;002-484-834-539-43X;;013-999-068-412-238;;159-966-370-938-701;;026-395-951-813-684;;042-899-467-629-059;;037-475-853-172-384;;072-202-121-867-696;;092-482-123-514-901;;041-128-004-154-032;;121-160-166-447-41X;;052-591-144-757-648;;013-647-036-572-027;;002-139-557-983-569;;041-128-004-154-032;;092-482-123-514-901;;042-899-467-629-059;;024-188-874-869-363,10.1146/annurev.neuro.18.1.159;;10.1146/annurev.ne.18.030195.001111;;7605059;;9034785;;10.1210/edrv.18.1.0292;;10.1210/er.18.1.26;;9874150;;10.1016/s0165-0270(98)00126-5;;10075850;;10.1006/dbio.1998.9192;;pmc6573198;;10.1523/jneurosci.17-15-05820.1997;;9221780;;10688783;;10.1126/science.287.5457.1433;;12383233;;10.1046/j.1460-9568.2002.02181.x;;9585351;;10.1002/ana.410430505;;10585297;;10.1006/excr.1999.4678;;10.1634/stemcells.18-4-295;;10924096;;1689217;;10.1016/0092-8674(90)90662-x;;11533656;;10.1038/ncb0901-778;;10.1126/science.290.5497.1779;;11099419;;11099418;;10.1126/science.290.5497.1775;;10.1073/pnas.94.8.4080;;pmc20571;;9108108;;10931522;;10.1002/1097-4547(20000815)61:4<364::aid-jnr2>3.0.co;2-c;;10.1002/1097-4547(20000815)61:4<364::aid-jnr2>3.3.co;2-3;;10915564;;10.1006/exnr.2000.7389;;10.1126/science.287.5457.1418;;10722390;;10636772;;10.1126/science.286.5448.2238;;10.1126/science.287.5457.1442;;10688785;;10722392;;10.1126/science.287.5457.1421;;10915564;;10.1006/exnr.2000.7389;;10931522;;10.1002/1097-4547(20000815)61:4<364::aid-jnr2>3.0.co;2-c;;10.1002/1097-4547(20000815)61:4<364::aid-jnr2>3.3.co;2-3;;10.1126/science.290.5497.1779;;11099419;;12077603;;10.1038/nature00870,"Gage et al. (1995) ""Isolation, characterization, and use of stem cells from the CNS,"" Annu Rev Neurosci. 18: 159-92.;;Bikfalvi et al. (1997) ""Biological Roles of Fibroblast Growth Factor-2"" Endocrine Reviews 18(1): 26-45.;;Svendsen et al. (Dec. 1, 1998) ""A new method for rapid and long term growth of human neural precursor cells"" Journal of Neuroscience Methods 85(2): 141-152.;;Tropepe et al., Developmental Biology 208: 166-188.;;U. Englund et al., ""Site-Specific Neuronal Differentiation of Growth Factor Expanded Human Neural Progenitor Cells After Transplantation to the Neonatal Rat Brain,"" Society for Neuroscience Abstracts, vol. 25, No. 1/2, p. 213 (1999).;;H.G. Kuhn et al., ""Epidermal Growth Factor and Fibroblast Growth Factor-2 have Different Effects on Neural Progenitors in the Adult Rat Brain,"" J. Neuroscience, vol. 17, No. 15, pp. 5820-5829 (1997).;;F.H. Gage, ""Mammalian Neural Stem Cells,"" Science, vol. 287, No. 5457, pp. 1433-1438 (2000).;;D.J. Martens et al., ""In Vivo Infusions of Exogenous Growth Factors into the Fourth Ventricle of the Adult Mouse Brain Increase the Proliferation of Neural Progenitors Around the Fourth Ventricle and the Central Canal of the Spinal Cord,"" European J. Neuroscience, vol. 16, No. 6, pp. 1045-1057 (2002).;;D. W. Pincus et al., ""Fibroblast Growth Factor-2/Brain-Derived Neurotrophic Factor-Associated Maturation of New Neurons Generated from Adult Human Subependymal Cells,"" Annals of Neurology, vol. 43, No. 5, pp. 576-585 (May 1998).;;C. B. Johansson et al., ""Rapid Communication-Neural Stem Cells in the Adult Human Brain,"" Experimental Cell Research, vol. 253, pp. 733-736 (1999).;;S. F. Pagano et al., ""Isolation and Characterization of Neural Stem Cells from the Adult Human Olfactory Bulb,"" Stem Cells 2000, vol. 18, pp. 295-300 (2000).;;U. Lendahl et al., ""CNS Stem Cells Express a New Class of Intermediate Filament Protein,"" Cell, vol. 60, No. 4, pp. 585-595 (Feb. 1990).;;J. G. Toma et al., ""Isolation of multipotent adult stem cells from the dermis of mammalian skin,"" Nature Cell Biology, vol. 3, pp. 778-784 (2001).;;E. Mezey et al., ""Turning Blood into Brain: Cells Bearing Neuronal Antigens Generated in Vivo from Bone Marrow,"" Science, vol. 290, pp. 1779-1782 (Dec. 2000).;;T. R. Brazelton et al., ""From Marrow to Brain: Expression of Neuronal Phenotypes in Adult Mice,"" Science, vol. 290, pp. 1775-1779 (Dec. 2000).;;M. A. Eglitis and E. Mezey, ""Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice,"" Proc. National Academy of Science USA/Neurobiology, vol. 94, pp. 4080-4085 (Apr. 1997).;;D. Woodbury et al., ""Adult Rat and Human Bone Marrow Stromal Cells Differentiate into Neurons,"" Journal of Neuroscience Research, vol. 61, pp. 364-370 (2000).;;J. Sancehz-Ramos et al., ""Adult Bone Marrow Stromal Cells Differentiate into Neural Cells in Vitro,"" Experimental Neurology, vol. 164, pp. 247-256 (2000).;;Vogel, Gretchen; ""Can Old Cells Learn New Tricks,"" The American Association for the Advancement of Science, vol. 287, No. 5457, pp. 1418-1419 (Feb. 25, 2000).;;Vogel, Gretchen; ""Capturing the Promise of Youth,"" The American Association for the Advancement of Science, vol. 286, No. 5448, pp. 2238-2239 (Dec. 17, 1999).;;Weissman, Irving L.; ""Translating Stem and Progenitor Cell Biology to the Clinic: Barriers and Opportunities,"" The American Association for the Advancement of Science, vol. 287, No. 5457, pp. 1442-1446 (Feb. 25, 2000).;;Barinaga, Marcia; ""Fetal Neuron Grafts Pave the Way for Stem Cell Therapies,"" The American Association for the Advancement of Science, vol. 287, No. 5457, pp. 1421-1422 (Feb. 25, 2000).;;Sanchez-Ramos, J., ""Adult Bone Marrow Stromal Cells Differentiate Into Neural Cells in Vitro"", Experimental Neurology, 164:247-256 (2000).;;Woodbury, D., ""Adult Rat and Human Bone Marrow Stromal Cells Differentiate Into Neurons"", Journal of Neuroscience Research 61:364-370 (2000).;;Mezey, E., ""Turning Blood into Brain: Cells Bearing Neuronal Antigens Generated in vivo from Bone Marrow"", Science 290:1779-1782 (Dec. 2000).;;Jiang, Y., ""Pluripotency of Mesenchymal Stem Cells Derived From Adult Marrow"", Nature, 418:41-49 (Jul. 2002).",EXPIRED
24,US,A1,US 2003/0082160 A1,006-590-550-673-156,2003-05-01,2003,US 25375902 A,2002-09-24,US 25375902 A;;US 33495701 P,2001-10-25,Differentiation of whole bone marrow,"
   A method is described for generating a clinically significant volume of neural progenitor cells from whole bone marrow. A mass of bone marrow cells may be grown in a culture supplemented with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). Further methods of the present invention are directed to utilizing the neural progenitor cells cultured in this fashion in the treatment of various neuropathological conditions, and in targeting delivery of cells transfected with a particular gene to diseased or damaged tissue. 
",YU JOHN S.;;KABOS PETER;;EHTESHAM MONEEB,YU JOHN S;;KABOS PETER;;EHTESHAM MONEEB,CEDARS-SINAI MEDICAL CENTER (2002-11-05),https://lens.org/006-590-550-673-156,Patent Application,yes,40,53,19,19,0,A61K35/12;;A61K38/00;;A61K48/00;;C12N5/0623;;C12N2501/11;;C12N2501/115;;C12N2506/11;;C12N2510/00;;C12N2506/1353;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;C12N5/0623;;A61K35/12;;C12N2501/11;;C12N2506/11;;A61K38/00;;C12N2501/115;;C12N2510/00;;A61K48/00;;C12N2506/1353,A61K35/12;;A61K35/30;;A61K38/00;;A61K48/00;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;C12N5/0797,424/93.21;;435/368,0,0,,,,EXPIRED
25,AT,T1,AT E387491 T1,068-609-986-754-439,2008-03-15,2008,AT 02784173 T,2002-10-18,US 33495701 P;;US 25375902 A,2001-10-25,DIFFERENZIERUNG VOM GESAMTEN KNOCHENMARK,The present invention relates to a method for generating a clinically significant volume of neural progenitor cells. The method comprises providing a mass of cells obtained from a mammal including at least one stem cell; and culturing the mass of cells in a medium comprising fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF) to produce a clinically significant volume of neural progenitor cells. The invention also concerns neural progenitor cells per se and their use in the treatment of neuropathologic conditions.,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;KABOS PETER;;EHTESHAM MONEEB,,https://lens.org/068-609-986-754-439,Granted Patent,no,0,0,19,19,0,A61K35/12;;A61K38/00;;A61K48/00;;C12N5/0623;;C12N2501/11;;C12N2501/115;;C12N2506/11;;C12N2510/00;;C12N2506/1353;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;C12N5/0623;;A61K35/12;;C12N2501/11;;C12N2506/11;;A61K38/00;;C12N2501/115;;C12N2510/00;;A61K48/00;;C12N2506/1353,A61K35/12;;A61K35/30;;A61K38/00;;A61K48/00;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;C12N5/0797,,0,0,,,,EXPIRED
26,EP,A1,EP 1956079 A1,095-191-750-344-162,2008-08-13,2008,EP 08075134 A,2002-10-18,EP 02784173 A;;US 33495701 P;;US 25375902 A,2001-10-25,Neural progenitor cells,The present invention relates to a method for generating a clinically significant volume of neural progenitor cells. The method comprises providing a mass of cells obtained from a mammal including at least one stem cell; and culturing the mass of cells in a medium comprising fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF) to produce a clinically significant volume of neural progenitor cells. The invention also concerns neural progenitor cells per se and their use in the treatment of neuropathologic conditions.,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;KABOS PETER;;EHTESHAM MONEEB,,https://lens.org/095-191-750-344-162,Patent Application,yes,7,1,19,19,0,A61K35/12;;A61K38/00;;A61K48/00;;C12N5/0623;;C12N2501/11;;C12N2501/115;;C12N2506/11;;C12N2510/00;;C12N2506/1353;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;C12N5/0623;;A61K35/12;;C12N2501/11;;C12N2506/11;;A61K38/00;;C12N2501/115;;C12N2510/00;;A61K48/00;;C12N2506/1353,C12N5/071;;A61K35/12;;A61K35/30;;A61K38/00;;A61K48/00;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;C12N5/0797,,14,12,041-128-004-154-032;;078-948-768-708-871;;082-231-208-545-177;;121-160-166-447-41X;;002-139-557-983-569;;015-375-563-301-698;;002-484-834-539-43X;;013-999-068-412-238;;042-899-467-629-059;;037-475-853-172-384;;072-202-121-867-696;;159-966-370-938-701,10915564;;10.1006/exnr.2000.7389;;10688781;;10.1126/science.287.5457.1427;;10688783;;10.1126/science.287.5457.1433;;10.1126/science.287.5457.1418;;10722390;;10722392;;10.1126/science.287.5457.1421;;9585351;;10.1002/ana.410430505;;10585297;;10.1006/excr.1999.4678;;10.1634/stemcells.18-4-295;;10924096;;10.1126/science.290.5497.1779;;11099419;;11099418;;10.1126/science.290.5497.1775;;10.1073/pnas.94.8.4080;;pmc20571;;9108108;;1689217;;10.1016/0092-8674(90)90662-x,"ENGLUND U ET AL: ""SITE-SPECIFIC NEURONAL DIFFERENTIATION OF GROWTH FACTOR EXPANDED HUMAN NEURAL PROGENITOR CELLS AFTER TRANSPLANTATION TO THE NEONATALRAT BRAIN"", SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, vol. 25, no. 1/2, 1999, pages 213, XP001002083, ISSN: 0190-5295;;SANCHEZ-RAMOS J ET AL: ""Adult bone marrow stromal cells differentiate into neural cells in vitro"", 1 August 2000, EXPERIMENTAL NEUROLOGY, ACADEMIC PRESS, NEW YORK, NY, US, PAGE(S) 247 - 256, ISSN: 0014-4886, XP002199139;;F. M. WATT; B. L. M. HOGAN: ""Out of Eden: Stem Cells and Their Niches"", SCIENCE, vol. 284, 2000, pages 1427 - 1430, XP000919226, DOI: doi:10.1126/science.287.5457.1427;;F. H. GAGE: ""Mammalian Neural Stem Cells"", SCIENCE, vol. 287, 2000, pages 1433 - 1488;;G. VOGEL: ""Can Old Cells Learn New Tricks?"", SCIENCE, vol. 287, 2000, pages 1418 - 1419;;M. BARINAGA: ""Fetal Neuron Grafts Pave the Way for Stem Cell Therapies"", SCIENCE, vol. 287, 2000, pages 1421 - 1422;;D.W. PINCUS ET AL., ANN. NEUROL., vol. 43, 1998, pages 576 - 585;;C.B. JOHANSSON, EXP. CELL. RES., vol. 253, 1999, pages 733 - 736;;S.F. PAGANO, STEM CELLS, vol. 18, 2000, pages 295 - 300;;J.G. TOMA ET AL., NAT. CELL BIOL., vol. 3, 2001, pages 778 - 783;;E. MEZEY, SCIENCE, vol. 290, 2000, pages 1779 - 1782;;T.R. BRAZLETON ET AL., SCIENCE, vol. 290, 2000, pages 1775 - 1779;;M.A. EGLITIS ET AL., PROC NATL. ACAD. SCI., vol. 94, 1997, pages 4080 - 4085;;U. LENDAHL ET AL., CEFT, vol. 60, 1990, pages 585 - 595",EXPIRED
27,KR,A,KR 20060116850 A,123-880-557-273-865,2006-11-15,2006,KR 20067016411 A,2006-08-16,KR 20067016411 A,2006-08-16,INTRATUMORAL DELIVERY OF DENDRITIC CELLS,Methods included herein describe the treatment of a tumor by administering dendritic cells either directly into the same or into its surrounding tissue. Further methods describe the induction of immune cell infiltration into tumors and the treatment of tumors with unprimed dendritic cells by administering dendritic cells in a similar fashion. The methods of the present invention are particularly advantageous in the treatment of brain tumors and other solid tumors disposed throughout the body of a mammal that are difficult or impossible to treat by conventional surgical means. Dendritic cell-based compositions effective in the treatment of such tumors are also described.,CEDARS SINAI MEDICAL CENTER,YU JOHN S;;BLACK KEITH;;EHTESHAM MONEEB,,https://lens.org/123-880-557-273-865,Patent Application,no,0,0,1,1,0,A61K9/0012;;A61K9/0019;;A61K35/15;;A61K35/28;;C12N2501/22;;C12N2501/2304,A61K35/14;;A61K35/16;;A61K35/28,,0,0,,,,DISCONTINUED
28,WO,A1,WO 2003/035855 A1,197-572-341-703-985,2003-05-01,2003,US 0233447 W,2002-10-18,US 33495701 P;;US 25375902 A,2001-10-25,DIFFERENTIATION OF WHOLE BONE MARROW,"A method is described for generating a clinically significant volume of neural progenitor cells from whole bone marrow. A mass of bone marrow cells may be grown in a culture supplemented with fibroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF). Further methods of the present invention are directed to utilizing the neural progenitor cells cultured in this fashion in the treatment of various neuropathological conditions, and in targeting delivery of cells transfected with a particular gene to diseased or damaged tissue.",CEDARS SINAI MEDICAL CENTER,YU JOHN S;;KABOS PETER;;EHTESHAM MONEEB,,https://lens.org/197-572-341-703-985,Patent Application,yes,2,0,19,19,0,A61K35/12;;A61K38/00;;A61K48/00;;C12N5/0623;;C12N2501/11;;C12N2501/115;;C12N2506/11;;C12N2510/00;;C12N2506/1353;;A61P25/00;;A61P25/28;;A61P35/00;;A61P43/00;;A61P9/00;;A61P9/10;;C12N5/0623;;A61K35/12;;C12N2501/11;;C12N2506/11;;A61K38/00;;C12N2501/115;;C12N2510/00;;A61K48/00;;C12N2506/1353,A61K35/12;;A61K35/30;;A61K38/00;;A61K48/00;;A61P9/00;;A61P9/10;;A61P25/00;;A61P25/28;;A61P35/00;;C12N5/0797,,4,3,012-177-818-988-764;;082-231-208-545-177;;003-096-082-862-593,pmc6573198;;10.1523/jneurosci.17-15-05820.1997;;9221780;;10688783;;10.1126/science.287.5457.1433;;12383233;;10.1046/j.1460-9568.2002.02181.x,"ENGLUND U ET AL: ""SITE-SPECIFIC NEURONAL DIFFERENTIATION OF GROWTH FACTOR EXPANDED HUMAN NEURAL PROGENITOR CELLS AFTER TRANSPLANTATION TO THE NEONATALRAT BRAIN"", SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, vol. 25, no. 1/2, 1999, pages 213, XP001002083, ISSN: 0190-5295;;KUHN H GEORG ET AL: ""Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain."", JOURNAL OF NEUROSCIENCE, vol. 17, no. 15, 1997, pages 5820 - 5829, XP002229396, ISSN: 0270-6474;;GAGE F H: ""MAMMALIAN NEURAL STEM CELLS"", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 287, no. 5457, 25 February 2000 (2000-02-25), pages 1433 - 1438, XP000919227, ISSN: 0036-8075;;MARTENS DAVID J ET AL: ""In vivo infusions of exogenous growth factors into the fourth ventricle of the adult mouse brain increase the proliferation of neural progenitors around the fourth ventricle and the central canal of the spinal cord."", EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 16, no. 6, September 2002 (2002-09-01), September, 2002, pages 1045 - 1057, XP002229397, ISSN: 0953-816X",PATENTED
